NR3C2 and plasma cell myeloma: We showed that a functional crosstalk between GR and MR exists in myeloma and that a targeting hereof with ligands warrants further investigation of its potential therapeutic benefit in terms of efficacy, safety and the possibility to reduce the GC-dose.